期刊文献+

妊娠期糖尿病患者骨钙素和β-胶原特殊序列水平分析 被引量:14

Detection of Serum Osteocalcin and β-CrossLaps Levels in Gestational Diabetes Mellitus
下载PDF
导出
摘要 目的分析妊娠期糖尿病患者骨钙素及β-胶原特殊序列水平的特点,为明确骨代谢与糖代谢之间相互作用的机制提供依据。方法病例对照研究。30例GDM患者纳入本研究(GDM组),收集血清检测血糖、N端骨钙素中分子片段和β-胶原特殊序列,另收集30例糖耐量正常的孕妇作为对照(NGT组)。结果 GDM组孕妇的骨钙素为14.95±4.16μg/L,高于NGT组的12.65±3.09μg/L(P=0.017);β-胶原特殊序列为0.339±-0.124μg/L,高于NGT组的0.272±0.086μg/L(P=0.018)。结论妊娠期糖尿病患者骨吸收代谢水平和骨转换率均高于一般孕妇,明确骨-糖代谢的相互作用尚需进一步深入研究。 Objective To investigate the characteristic of serum osteocalcin and β-Cross Laps level in gestational diabetes mellitus. Methods 30 gestational diabetic patients(GDM group) and 30 pregnant women with normal glucose tolerance( NGT group) were included in this study. 3he levels of serum glucose,N-MID osteocalcin and β- cmsslaps were detected and compared. Results Serum N-MID osteocalcin and β-crosslaps levels in GDM group were significantly higher than those in NGT group(P =0.017 and P =0. 018, respectively). Conclusion Bone resorption and turnover level in gestational diabetic patients are higher than pregnmat women with normal glucose tolerance.
出处 《标记免疫分析与临床》 CAS 2015年第1期10-11,共2页 Labeled Immunoassays and Clinical Medicine
关键词 妊娠期糖尿病 骨代谢 骨钙素 β-胶原特殊序列 Gestational diabetes mellitus Bone metabolism Osteocalcin β- CrossLaps
  • 相关文献

同被引文献98

  • 1贺立侠,金秀平,刘佳明,万秋霞.探讨2型糖尿病性骨质疏松患者骨代谢指标水平变化及其影响因素[J].兰州大学学报(医学版),2018,0(6):45-49. 被引量:11
  • 2黄江渝,胡汶竹.血清骨钙素水平检测的临床应用现状[J].现代预防医学,2007,34(9):1674-1675. 被引量:53
  • 3无.妊娠合并糖尿病临床诊断与治疗推荐指南(草案)[J].中华围产医学杂志,2007,10(4):283-285. 被引量:148
  • 4Bjarnason NH, Christiansen C. Early response in biochemical mark- ers predicts long-term response in bone mass during hormone replace- ment therapy in early postmenopausal women [J]. Bone, 2000, 26 (6) : 561-569.
  • 5Garnero P, Somay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study [J]. J Bone Miner Res, 2000, 15(8): 1526-1536.
  • 6Vasikaran S, Cooper C, Eastell R, et al. International osteoporosis foundation and intemational federation of clinical chemistry and labo- ratory medicine position on bone marker standards in osteoporosis [J]. Clin Chem Lab Med, 2011, 49(8) : 1271-1274.
  • 7Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treat- ment: a need for international reference standards [J]. Osteoporos Int, 2011,22(2) :391-420.
  • 8Steelman J, Zeitler P. Osteoporosis in Pediatrics [J]. Pediatr Rev, 2001, 22(2) :56-65.
  • 9Hernandez CJ, Beaupr GS, Carter DR. A theoretical analysis of the relative influences of peak BMD, age related bone loss and meno- pause on the development of osteoporosis [J]. Osteoporos Int, 2003, 14(10) :843-847.
  • 10Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature ,2003,423 (6937) :349-355.

引证文献14

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部